Shares

11 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 09, 2024

BUY
$1.11 - $1.85 $44,400 - $74,000
40,000 Added 29.9%
173,800 $201,000
Q1 2024

May 13, 2024

BUY
$1.63 - $3.08 $153,383 - $289,828
94,100 Added 237.03%
133,800 $256,000
Q4 2023

Feb 13, 2024

BUY
$1.07 - $3.07 $42,479 - $121,879
39,700 New
39,700 $108,000
Q4 2022

Feb 13, 2023

BUY
$1.99 - $3.52 $21,575 - $38,163
10,842 Added 82.24%
24,025 $56,000
Q3 2022

Nov 14, 2022

SELL
$3.09 - $5.23 $635,613 - $1.08 Million
-205,700 Reduced 93.98%
13,183 $41,000
Q2 2022

Aug 12, 2022

SELL
$2.58 - $4.99 $1.43 Million - $2.76 Million
-554,000 Reduced 71.68%
218,883 $985,000
Q1 2022

May 13, 2022

BUY
$3.93 - $7.7 $3.04 Million - $5.95 Million
772,883 New
772,883 $3.04 Million
Q1 2020

May 14, 2020

SELL
$7.54 - $17.05 $336,155 - $760,140
-44,583 Closed
0 $0
Q4 2019

Feb 13, 2020

BUY
$6.71 - $9.55 $299,151 - $425,767
44,583 New
44,583 $408,000
Q2 2019

Aug 12, 2019

SELL
$3.77 - $8.67 $669,552 - $1.54 Million
-177,600 Closed
0 $0
Q1 2019

May 14, 2019

BUY
$2.58 - $3.54 $458,208 - $628,704
177,600 New
177,600 $629,000

Others Institutions Holding CVM

About CEL SCI CORP


  • Ticker CVM
  • Exchange NYSE
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 43,367,500
  • Market Cap $26.9M
  • Description
  • CEL-SCI Corporation engages in the research and development of immunotherapy for the treatment of cancer and infectious diseases. The company's lead investigational immunotherapy is Multikine, which is under phase III clinical trial for the treatment of head and neck cancer. Its Ligand Epitope Antigen Presentation System (LEAPS), a pre-clinical ...
More about CVM
Track Jim Simons's Portfolio

Track Jim Simons Portfolio

Follow Jim Simons (Renaissance Technologies LLC) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Renaissance Technologies LLC, based on Form 13F filings with the SEC.

News

Stay updated on Renaissance Technologies LLC and Jim Simons with notifications on news.